The glycoprotein prosaposin has previously been demonstrated to inhibit tumour metastasis in lung and breast cancer models through stimulation of monocyte production of the antitumorigenic protein thrombospondin 1 (TSP1). Here, Wang et al. report that a cyclic peptide derived from the active sequence in prosaposin promotes tumour regression in a patient-derived tumour xenograft model of metastatic ovarian cancer. Analysis of tumour tissue from 134 patients with serous ovarian cancer revealed that 97% of the tumours expressed CD36, the receptor that mediates the pro-apoptotic activity of TSP1.
References
Wang, S. et al. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci. Transl Med. 8, 329ra34 (2016)
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Cyclic peptide inhibits metastases. Nat Rev Drug Discov 15, 310 (2016). https://doi.org/10.1038/nrd.2016.78
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.78